Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ANV419 as Monotherapy, and ANV419 in Combination With Daratumumab or With Lenalidomide Plus Low-Dose Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma (OMNIA-2)

NCT05641324 is registered in ClinicalTrials.gov with Anaveon AG as lead sponsor.

NCT NCT05641324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05641324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ANV419 as Monotherapy, and ANV419 in Combination With Daratumumab or With Lenalidomide Plus Low-Dose Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma (OMNIA-2)
Lead sponsor
Anaveon AG
Phase
Phase 1
Overall status
Terminated
Start date
February 10, 2023
Completion date
July 12, 2023
Enrollment
4 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

adult disease, hematologic diseases, multiple myeloma, refractory multiple myeloma, relapsed cancer